Taheebo

Generic name: Tabebuia Avellanedae Lorentz Ex Griseb.
Brand names: Ipé Roxo, Lapacho Colorado, Lapacho Morado, Pau D'Arco, Red Lapacho, Taheebo

Usage of Taheebo

Commercially available botanical drug material is of varying quality and composition,(Gómez CastEllanos 2009) making assessments of product clinical efficacy challenging; the bioscientific evidence for products derived from T. impetiginosa is insufficient. When pharmacologic actions of the whole plant extract were compared with those of its isolated constituents, potency appeared to decline with purification.(Gómez Castellanos 2009)

Various fractions from T. avellanedae have shown astringent, anti-inflammatory, antibacterial, antifungal, diuretic, anticoagulant, laxative, and anticancer properties, among others.(Byeon 2008) However, no clinical studies of preparations derived from taheebo have been conducted.

Anti-inflammatory activity

Animal and in vitro data

In an in vitro study, 5 novel compounds isolated from the water extract of T. avellanedae showed anti-inflammatory properties.(Suo 2012) The water extract of T. avellanedae blocks inflammatory mediators in vitro and in vivo; it suppresses the production of prostaglandin E2 and nitric oxide and blocks the mRNA expression of their catalyzing enzymes.(Byeon 2008, Zhang 2016) In an in vivo study in mice, a 200 mg/kg dose of taheebo ethanolic extract showed anti-inflammatory effects.(Lee 2012) In a mouse macrophage line, taheebo polyphenols reversed free fatty acid–induced increases in inflammatory markers in a dose-Dependent manner, without affecting overall cell viability. The mechanism involved reversal of upregulation of cyclooxygenase 2 (COX-2) mRNA more than of COX-1.(Ma 2017)

Antimicrobial activity

In vitro data

In studies evaluating the antimicrobial activity of T. impetiginosa, methanol extracts of the inner bark showed weak to moderate activity against Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus casei, and EscheriChia coli, and strong activity against Clostridium paraputrificum, Clostridium perfringes, and Helicobacter pylori. The 2 compounds thought to be responsible for the antibacterial activity were lapachol and anthraquinone-2-carboxyl acid. In a study evaluating the activity of taheebo against H. pylori, lapachol was more effective than metronidazole, but far less effective than amoxicillin and tetracycline.(Gómez Castellanos 2009, Park 2005, Park 2006) When tested in vitro against methicillin-resistant Staphylococcus aureus, beta-lapachone demonstrated synergistic activity with conventional agents (eg, beta-lactams, fluoroquinolones, carbapenems).(Macedo 2013) Lapachol has demonstrated activity against mycobacteria. In cell culture, lapachol was more effective intracellularly than extracellularly and demonstrated immunomodulatory effects (inhibition of the surface expression of the costimulatory molecule cluster of differentiation 86 [CD86]), which may enhance the capability of the host cell to control mycobacterial invasion.(Oliveira 2010)

Antiparasitic activity

Animal and in vitro data

In an in vitro study, lapachol and antimony, bismuth, and tin complexes of lapachol demonstrated antiparasitic activity.(Barbosa 2014, Rocha 2013) In various experiments, Tabebuia extracts inhibited interleukin 2 (IL-2)–dependent T-lymphocyte activation and proliferation, but had no effect on cytokine expression (IL-2 and tumor necrosis factor alpha). Immune inhibitory effects of Tabebuia were not mediated by beta-lapachone and were observed in aqueous but not ethanol extracts.(Böhler 2008) When antileishmanial activity of lapachol, isolapachol, and dihydrolapachol, as well as various soluble derivatives, was tested in vitro and in vivo, all lapachol compounds demonstrated activity against Leishmania in vitro; in vivo, a difference between treated and untreated mice was observed with only 1 of the 5 tested compounds 5 weeks after parasite injection. No toxicity was evident at concentrations similar to the 50% inhibitory concentration.(Lima 2004) Lapachol, beta-lapachone, and their derivatives demonstrated anthelmintic activity against Toxocara canis larvae both in vitro and in vivo in mice.(Mata-Santos 2015)

Antipsoriatic activity

In vitro data

In vitro, beta-lapachone has been shown to have antipsoriatic activity.(Gómez Castellanos 2009)

Cancer

In vitro data

In a series of studies, T. impetiginosa showed activity against a wide range of cancer cell lines, including Walker 256 carcinoma, prostate cancer, human promyelocytic leukemia, breast cancer, ovarian cancer, epidermoid laryngeal cancer, esophageal cancer, radioresistant human malignant melanoma, lung adenocarcinoma, cervical cancer, and osteosarcoma cells.(Bang 2016, Gómez Castellanos 2009, Inagaki 2013, Inagaki 2015, Kandioller 2013, Mukherjee 2009, Rao 1968, Sunassee 2013)

Beta-lapachone is considered the main antitumor compound, demonstrating activity against several tumor cell lines, including leukemia, lung, prostate, and breast cancers, as well as several multidrug-resistant cell lines.(Gómez Castellanos 2009, Kung 2014)

Lapachol is purported to have anticancer properties. While the mechanism of action is unknown, lapachol is involved in the inhibition of oxidative phosphorylation, activation of CYP-450 reductase, and enhancement of peroxidation of lipids in sarcoma cells.(Balassiano 2005, Fiorito 2014) Studies in cell cultures show that lapachol causes alterations in the protein profile and inhibits cellular invasiveness in HeLa cells (a human cancer cell line), suggesting antimetastatic activity.(Balassiano 2005)

Another potential anticancer mechanism proposed is the inhibition of topoisOmerase I. Investigations show that lapachol induces oxidative stress via generation of Reactive oxygen species, which leads to apoptosis and cell cycle arrest.(Kandioller 2013) In other research, beta-lapachone initiated apoptosis only in transformed cells without causing DNA damage.(Gómez Castellanos 2009) Furthermore, beta-lapachone increased activation of pro-apoptotic factor JNK and decreased activation of the cell survival/proliferation factors PI3K, AKT, and ERK.(Kung 2014) Beta-lapachone reportedly induces apoptosis by modulating E2F-1 expression, which activates the G1/S-phase checkpoint.(Shapiro 2005) An aqueous extract of pau d'arco stimulated the MAPK/ERK 1/2 pathway, leading to stimulation of nuclear factor erythroid 2–related factor 2 (Nrf2)–dependent gene expression.(Richter 2014) In vitro research using an aqueous extract of taheebo in estrogen receptor–positive breast cancer cells demonstrated upregulation of apoptosis-specific and xenobiotic metabolism–specific genes and downregulation of cell cycle regulatory and estrogen-responsive genes.(Mukherjee 2009) In the presence of probiotics, lapachol can be converted to a more active cytotoxic compound against breast cancer cell lines than lapachol alone.(Oliveira Silva 2014)

It is generally understood that nicotinamide adenine dinucleotide (NAD)(P)H:quinone oxidoreductase (NQ01) activity is an important determinant of beta-lapachone cytotoxicity and that NQ01 is overexpressed in most common types of cancer. NQ01 catalyzes the redox cycling of beta-lapachone via production of an unstable hydroquinone. Under aerobic conditions, this unstable quinone is quickly oxidized back to the parent Quinine, resulting in futile cycling between the 2 forms of beta-lapachone and a rapid increase in intracellular calcium, mitochondrial membrane depolarization, loss of adenosine triphosphate, DNA fragmentation, and, finally, apoptosis. Beta-lapachone acts, in part, through upregulation of NQ01.(Lamberti 2013) In leukemia cells, beta-lapachone is directly cytotoxic. It decreases cell viability and telomerase activity resulting from downregulation of telomerase reverse transcriptase.(Moon 2010)

Clinical data

The NCI studied the anticancer effects of the lapachol component of taheebo in the 1960s. Phase 1 clinical trials evaluating oral lapachol doSages of up to 4,000 mg/day showed no therapeutic effect, and it was determined that inadequate serum concentrations were achieved with oral administration. The Investigational New Drug Application for lapachol was closed in 1970.(Gómez Castellanos 2009, Kung 2014)

A series of phase 1 and 2 clinical trials have been conducted with beta-lapachone (ARQ 501) in patients with cancer. Early signs of clinical activity were demonstrated.(Hartner 2007, Khong 2007, Shapiro 2005)

Colitis

Animal data

In a murine model, oral administration of T. avellanedae water extract was protective against induced colitis. Mice treated with the extract exhibited much less diarrhea and less fecal blood. The mechanism involved induction of the differentiation of anti-inflammatory T-helper cells (ie, Th2, Treg), decreases in proinflammatory cytokines (ie, IL-12, IL-6, tumor necrosis factor alpha), and increases in the anti-inflammatory cytokine IL-10 in intestinal dendritic cells and macrophages from mesenteric lymph nodes.(Park 2017)

Dermatitis

Animal data

In an atopic dermatitis mouse model, oral administration of an ethanol extract of T. avellanedae ameliorated dermatitis-like symptoms, decreased dermatitis scores, and prevented the epidermal thickening observed in untreated controls in a dose-dependent manner. These effects at 120 mg/kg and 240 mg/kg doses were comparable to the effects of prednisolone. Mechanisms involved reductions in Histamine, immunoglobulin E, IL-4, IL-5, and proinflammatory cytokines (ie, interferon-gamma), with the 240 mg/kg dose being comparable to prednisolone.(Park 2018)

Endurance capacity

Animal data

A single dose of taheebo water extract increased endurance capacity (eg, running time) as well as plasma glucose and glycogen levels in the skeletal muscles of mice. In contrast, glycerol in skeletal muscle and the liver decreased, as did blood Urea nitrogen.(Yada 2018)

Hypotensive effects

Animal data

Evidence in rats suggests that a seminatural naphthoquinone derivative of lapachol, 3-hydroxy-4-(hydroxyimino)-2-(3-methybut-2-enylnaphtalen-2[4H])-one can induce hypotension.(Dantas 2014)

Obesity

Animal data

In mice fed a high-fat diet, administration of an ethanolic extract of taheebo (150 mg/kg of body weight daily by gavage) interfered with obesity and fat accumulation by regulating gene expression related to lipid metabolism.(Choi 2014) In ovariectomized mice with high-fat diet–induced obesity (menopause-induced obesity model), oral administration of an n-bUTAnol taheebo extract led to reductions in body weight, peritubal fat, perirenal fat, and mesenteric fat compared with controls, with no difference in food intake. No differences were found in organ weights, lipid parameters, adiponectin, resistin, or serum glucose between the 2 groups.(Iwamoto 2016)

Osteoarthritis

Animal data

In a rat model of osteoarthritis, oral administration of an ethanol extract of T. avellanedae increased the pain threshold in a manner comparable to positive controls without side effects. The effect was observed at low doses and was not dose dependent. Severe degradation of articular cartilage observed in untreated controls was inhibited with taheebo extract, which also exhibited a dose-dependent chondroprotective effect that was better than the positive control methylsulfonylmethane. X-ray results cOnfirmed the histopathological outcomes.(Park 2017)

Vascular effects

In vitro data

Taheebo is capable of inhibiting platelet aggregation and vascular smooth muscle proliferation. While the mechanism of action is unclear, the antiplatelet effects may be due to suppression of arachidonic acid and collagen liberation, and the inhibition of vascular smooth muscle proliferation may be due to suppression of phosphorylated mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) activation.(Son 2006)

Wound healing

Animal and in vitro data

In a study in mice, scrape or burn wounds treated with beta-lapachone ointment healed faster than those treated with a control ointment. In cell cultures, beta-lapachone induced macrophage proliferation and increased vascular endothelial growth factor release from macrophages.(Fu 2011, Kung 2008)

Taheebo side effects

Taheebo is generally considered safe.(Gómez Castellanos 2009)

The isolated compound lapachol is associated with interference with the biological cycle of vitamin K. When consumed as red lapacho tea, which contains all components of taheebo including some pro–vitamin K compounds, the effect appears to be canceled.(Gómez Castellanos 2009)

Exposure to wood and/or wood dust from Tabebuia spp. can lead to asthma(Algranti 2005) and fixed eruption (erythematous, pruritic, hyperpigmented skin eruptions).(Landry 2018)

Pau d'arco tea can reportedly cause nausea and vomiting.(Cheng 2012)

Hemolytic anemia has been reported as a limiting toxicity in animals.(Lima 2004)

When administered to patients with cancer, beta-lapachone did not exhibit dose-limiting toxicity. Adverse events were mild and included anemia, hemolysis, hyperbilirubinemia, edema, nausea, constipation, and fatigue.(Hartner 2007, Khong 2007, Shapiro 2005)

Before taking Taheebo

Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking.

How to use Taheebo

Clinical information is lacking to provide dosing recommendations.

Warnings

No toxicity has been reported in humans for the bark extract or its main constituents.

What other drugs will affect Taheebo

None well documented.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords